2839-LB: A Long-Acting Quintuple Agonist for the GLP-1, GIP, Glucagon, Amylin, and Calcitonin Receptors Induces Greater Weight Loss than Retatrutide in Obese Rats
Diabetes · 05.06.2026 · 75 (Supplement_1)
DOI: 10.2337/db26-2839-lb ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes, erschienen am 05.06.2026. Verfasst von JONATHAN DOUROS und 5 weiteren Autor:innen.
Abstract (Originalsprache)
Introduction and Objective: Obesity is a leading driver of cardiometabolic disease that affects more than 130 million people in the United States. Although current obesity pharmacotherapies can reduce body weight by up to 25% in clinical trials, evidence from bariatric surgery cohorts demonstrates that weight loss exceeding 30% yields even greater metabolic benefits. This highlights the need for next-generation treatments capable of achieving greater efficacy in order to provide greater metabolic disease resolution, particularly for patients with severe disease burden Methods: We have developed VRX-0075, a long-acting quintuple agonist targeting the GLP-1, GIP, glucagon, amylin, and calcitonin receptors.
Results
VRX-0075 exhibits in vitro potency comparable to retatrutide at the GLP-1, GIP, and glucagon receptors, while matching the potency of cagrilintide at the amylin and calcitonin receptors. In obese rats, VRX-0075 demonstrates a half-life approximately 50% longer than semaglutide, suggesting that it is suitable for weekly dosing in humans. Importantly, VRX-0075 induces significantly greater weight loss in obese rats than retatrutide at the same molar dose with no observable toxicology findings in a non-regulatory setting.
Conclusion
Collectively, these findings support VRX-0075 as a development candidate for achieving best-in-class cardiometabolic disease resolution in patients with obesity. Disclosure J. Douros: Research Support; Current; Eli Lilly and Company. S. Mowery: Research Support; Current; Eli Lilly and Company. M. Kalwat: Research Support; Current; Eli Lilly and Company. Stock/Shareholder; Current; Pfizer Inc. S. Dodson: None. R. Shrinivasan: None. P.J. Knerr: Stock/Shareholder; Current; Novo Nordisk. Research Support; Current; Eli Lilly and Company. Stock/Shareholder; Current; Volari Therapeutics.
Zitieren
APA
DOUROS, J., MOWERY, S., KALWAT, M., DODSON, S., SHRINIVASAN, R., & KNERR, P. J. (2026). 2839-LB: A Long-Acting Quintuple Agonist for the GLP-1, GIP, Glucagon, Amylin, and Calcitonin Receptors Induces Greater Weight Loss than Retatrutide in Obese Rats. Diabetes, 75(Supplement_1). https://doi.org/10.2337/db26-2839-lb
Vancouver
DOUROS J, MOWERY S, KALWAT M, DODSON S, SHRINIVASAN R, KNERR PJ. 2839-LB: A Long-Acting Quintuple Agonist for the GLP-1, GIP, Glucagon, Amylin, and Calcitonin Receptors Induces Greater Weight Loss than Retatrutide in Obese Rats. Diabetes. 2026;75(Supplement_1). doi:10.2337/db26-2839-lb
BibTeX
@article{DOUROS2026,
author = {DOUROS, JONATHAN and MOWERY, STEPHANIE and KALWAT, MICHAEL and DODSON, SCOTT and SHRINIVASAN, RASHMI and KNERR, PATRICK J.},
title = {2839-LB: A Long-Acting Quintuple Agonist for the GLP-1, GIP, Glucagon, Amylin, and Calcitonin Receptors Induces Greater Weight Loss than Retatrutide in Obese Rats},
journal = {Diabetes},
year = {2026},
volume = {75},
number = {Supplement_1},
doi = {10.2337/db26-2839-lb}
}
EUVIMED